{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:52:56Z","timestamp":1648882376482},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T00:00:00Z","timestamp":1464048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s11883-016-0593-2","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T19:37:50Z","timestamp":1464118670000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monoclonal Antibodies for Lipid Management"],"prefix":"10.1007","volume":"18","author":[{"given":"Matthew J.","family":"Feinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M.","family":"Lloyd-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"593_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","volume":"55","author":"WB Kannel","year":"1961","unstructured":"Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes 3rd J. Factors of risk in the development of coronary heart disease\u2014six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33\u201350.","journal-title":"Ann Intern Med"},{"key":"593_CR2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrcardio.2014.26","volume":"11","author":"ND Wong","year":"2014","unstructured":"Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11:276\u201389.","journal-title":"Nat Rev Cardiol"},{"key":"593_CR3","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0002-8703(85)90224-8","volume":"110","author":"WB Kannel","year":"1985","unstructured":"Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100\u20137.","journal-title":"Am Heart J"},{"key":"593_CR4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.ATV.20.3.830","volume":"20","author":"BV Howard","year":"2000","unstructured":"Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000;20:830\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"593_CR5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet"},{"key":"593_CR6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"593_CR7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"C Cholesterol Treatment Trialists","year":"2012","unstructured":"Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390.","journal-title":"Lancet"},{"key":"593_CR8","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"593_CR9","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med"},{"key":"593_CR10","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"AS Group","year":"2010","unstructured":"Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"593_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"HTC Group","year":"2014","unstructured":"Group HTC, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"593_CR12","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"A-H Investigators","year":"2011","unstructured":"Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"593_CR13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849\u201361.","journal-title":"Lancet"},{"key":"593_CR14","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u201399.","journal-title":"N Engl J Med"},{"key":"593_CR15","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"593_CR16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","volume":"67","author":"SA Murphy","year":"2016","unstructured":"Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67:353\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"593_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136.","journal-title":"Nat Genet"},{"key":"593_CR18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","volume":"32","author":"JD Horton","year":"2007","unstructured":"Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32:71\u20137.","journal-title":"Trends Biochem Sci"},{"issue":"Suppl","key":"593_CR19","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172\u20137.","journal-title":"J Lipid Res"},{"key":"593_CR20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","volume":"24","author":"K Ouguerram","year":"2004","unstructured":"Ouguerram K, Chetiveaux M, Zair Y, et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004;24:1448\u201353.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"593_CR21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/hmg\/ddi128","volume":"14","author":"XM Sun","year":"2005","unstructured":"Sun XM, Eden ER, Tosi I, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005;14:1161\u20139.","journal-title":"Hum Mol Genet"},{"key":"593_CR22","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S, Rhainds D, Essalmani R, et al. NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279:48865\u201375.","journal-title":"J Biol Chem"},{"key":"593_CR23","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101:7100\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"593_CR24","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","volume":"279","author":"SW Park","year":"2004","unstructured":"Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver. J Biol Chem. 2004;279:50630\u20138.","journal-title":"J Biol Chem"},{"key":"593_CR25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"593_CR26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161\u20135.","journal-title":"Nat Genet"},{"key":"593_CR27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCGENETICS.108.828467","volume":"2","author":"CC Huang","year":"2009","unstructured":"Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet. 2009;2:354\u201361.","journal-title":"Circ Cardiovasc Genet"},{"key":"593_CR28","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372.","journal-title":"N Engl J Med"},{"key":"593_CR29","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","volume":"284","author":"S Poirier","year":"2009","unstructured":"Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284:28856\u201364.","journal-title":"J Biol Chem"},{"key":"593_CR30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11:367\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"593_CR31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, Poss J, Bohm M, Laufs U. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"593_CR32","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"593_CR33","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891\u2013900.","journal-title":"N Engl J Med"},{"key":"593_CR34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29\u201336.","journal-title":"Lancet"},{"key":"593_CR35","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007\u201317.","journal-title":"Lancet"},{"key":"593_CR36","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408\u201317.","journal-title":"Circulation"},{"key":"593_CR37","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995\u20132006.","journal-title":"Lancet"},{"key":"593_CR38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497\u2013506.","journal-title":"JAMA"},{"key":"593_CR39","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186\u201394.","journal-title":"Eur Heart J"},{"key":"593_CR40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","volume":"28","author":"JJ Kastelein","year":"2014","unstructured":"Kastelein JJ, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther\/Sponsored Int Soc Cardiovasc Pharmacother. 2014;28:281\u20139.","journal-title":"Cardiovasc Drugs Ther\/Sponsored Int Soc Cardiovasc Pharmacother"},{"key":"593_CR41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906\u2013915 e13. This trial evaluated efficacy and safety of alirocumab versus placebo in addition to stable maximally tolerated statin therapy for high cardiovascular risk patients. Alirocumab resulted in a mean 48\u00a0% decrease in LDL cholesterol with comparable adverse event rates compared with placebo.","journal-title":"Am Heart J"},{"key":"593_CR42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758\u201369. This trial of alirocumab versus ezetimibe in hypercholesterolemic, statin-intolerant patients found that alirocumab reduced mean LDL cholesterol by 45\u00a0%, compared with 15\u00a0% for ezetimibe.","journal-title":"J Clin Lipidol"},{"key":"593_CR43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/clc.22327","volume":"37","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014;37:597\u2013604.","journal-title":"Clin Cardiol"},{"key":"593_CR44","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399. This trial evaluated alirocumab versus placebo over 78\u00a0weeks, representing the longest published follow-up to date from a phase III trial of PCSK9 inhibitors. In this trial, alirocumab added to maximal tolerated statin therapy demonstrated a sustained reduction in LDL cholesterol. Significantly, there was also a reduced rate of cardiovascular events in the alirocumab group.","journal-title":"N Engl J Med"},{"key":"593_CR45","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809\u201319.","journal-title":"N Engl J Med"},{"key":"593_CR46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234\u201343.","journal-title":"Circulation"},{"key":"593_CR47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341\u201350.","journal-title":"Lancet"},{"key":"593_CR48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331\u201340. This trial of evolocumab versus placebo among patients with heterozygous familial hypercholesterolemia found that evolocumab was generally well-tolerated over 12\u00a0weeks (with similar adverse event rates to placebo) and resulted in a mean LDL cholesterol reduction of 60\u00a0% compared with placebo.","journal-title":"Lancet"},{"key":"593_CR49","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870\u201382.","journal-title":"JAMA"},{"key":"593_CR50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541\u20138. This trial evaluated evolocumab versus ezetimibe in hypercholesterolemic, statin-intolerant patients. The central finding was that evolocumab substantially reduced LDL cholesterol from baseline and had fewer muscle-related adverse events.","journal-title":"J Am Coll Cardiol"},{"key":"593_CR51","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139. This trial evaluated evolocumab over a mean follow-up of 11.1\u00a0months and demonstrated sustained LDL cholesterol lowering as well as significantly decreased risks for cardiovascular events in the evolocumab arm. Importantly, this trial was open-label and did not have a placebo comparison group.","journal-title":"N Engl J Med"},{"key":"593_CR52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/003591576505800503","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The environment and disease: association or causation? Proc Royal Soc Med. 1965;58:295\u2013300.","journal-title":"Proc Royal Soc Med"},{"key":"593_CR53","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","volume":"29","author":"MA Evans","year":"2009","unstructured":"Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800\u201311.","journal-title":"Pharmacotherapy"},{"key":"593_CR54","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","volume":"88","author":"KJ Swiger","year":"2013","unstructured":"Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88:1213\u201321.","journal-title":"Mayo Clin Proc"},{"key":"593_CR55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","volume":"159","author":"K Richardson","year":"2013","unstructured":"Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159:688\u201397.","journal-title":"Ann Intern Med"},{"key":"593_CR56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","volume":"30","author":"BR Ott","year":"2015","unstructured":"Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30:348\u201358.","journal-title":"J Gen Intern Med"},{"key":"593_CR57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/gps.3797","volume":"28","author":"B McGuinness","year":"2013","unstructured":"McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Cochrane review on 'Statins for the treatment of dementia'. Int J Geriatr Psychiatry. 2013;28:119\u201326.","journal-title":"Int J Geriatr Psychiatry"},{"key":"593_CR58","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/hep.1840170625","volume":"17","author":"JB Wahler","year":"1993","unstructured":"Wahler JB, Swain MG, Carson R, Bergasa NV, Jones EA. Blood\u2013brain barrier permeability is markedly decreased in cholestasis in the rat. Hepatology. 1993;17:1103\u20138.","journal-title":"Hepatology"},{"key":"593_CR59","first-page":"35","volume":"28","author":"JA Joseph","year":"1996","unstructured":"Joseph JA, Denisova N, Villalobos-Molina R, Erat S, Strain J. Oxidative stress and age-related neuronal deficits. Mol Chem Neuropathol\/Sponsored Int Soc Neurochem World Fed Neurol Res Groups Neurochem Cerebrospinal Fluid. 1996;28:35\u201340.","journal-title":"Mol Chem Neuropathol\/Sponsored Int Soc Neurochem World Fed Neurol Res Groups Neurochem Cerebrospinal Fluid"},{"key":"593_CR60","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","volume":"43","author":"JH O'Keefe Jr","year":"2004","unstructured":"O'Keefe Jr JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"593_CR61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4065\/79.1.101","volume":"79","author":"JH O'Keefe Jr","year":"2004","unstructured":"O'Keefe Jr JH, Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. Mayo Clin Proc. 2004;79:101\u20138.","journal-title":"Mayo Clin Proc"},{"key":"593_CR62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","volume":"38","author":"KJ Swiger","year":"2015","unstructured":"Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf. 2015;38:519\u201326.","journal-title":"Drug Saf"},{"key":"593_CR63","doi-asserted-by":"crossref","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, Minissian MB, Orringer CE, and Smith SC. 2016 ACC expert consensus decision pathway on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol 2016;S0735-1097(16)32398-1.","DOI":"10.1016\/j.jacc.2016.03.519"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-016-0593-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0593-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T19:33:53Z","timestamp":1567971233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-016-0593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s11883-016-0593-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]},"article-number":"39"}}